Practice-changing studies in frontline and relapsed/refractory chronic lymphocytic leukemia (CLL), presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition ...

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

CLL is a chronic illness and is rarely curable ... You may be able to find a group through your local hospital or the Leukemia and Lymphoma Society. A cancer like CLL can take over every part ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...

Environmental toxins like pesticides and heavy metals can lead to blood cancer. Learn how genetics, lifestyle, and exposure ...